Results 51 to 60 of about 344,680 (247)

Epigenetic regulation of CD38/CD48 by KDM6A mediates NK cell response in multiple myeloma

open access: yesNature Communications
Anti-CD38 monoclonal antibodies like Daratumumab (Dara) are effective in multiple myeloma (MM); however, drug resistance ultimately occurs and the mechanisms behind this are poorly understood.
Jiye Liu   +21 more
doaj   +1 more source

High-Order Fiber Mode Beam Parameter Optimization for Transport and Rotation of Single Cells

open access: yesMicromachines, 2021
Optical tweezers are becoming increasingly important in biomedical applications for the trapping, propelling, binding, and controlled rotation of biological particles.
Zihao Shan   +7 more
doaj   +1 more source

Extramedullary Plasmacytoma of Soft Tissues and Gingiva [PDF]

open access: yes, 2012
Extramedullary plasmacytoma (EMP) is a rare plasma cell neoplasm of soft tissue without bone marrow involvement or other systemic characteristics of multiple myeloma. It accounts for 3% of all plasma cell tumors.
Jena, M, Kaler, AK, Shankar, A
core  

Disruption of HOX activity leads to cell death that can be enhanced by the interference of iron uptake in malignant B cells. [PDF]

open access: yes, 2010
The HOX genes encode a family of transcription factors that are dysregulated in several malignancies and have been implicated in oncogenesis and cancer cell survival.
Daniels, TR   +5 more
core   +1 more source

Targeting B Cell Maturation Antigen (BCMA) in Multiple Myeloma: Potential Uses of BCMA-Based Immunotherapy

open access: yesFrontiers in Immunology, 2018
The approval of the first two monoclonal antibodies targeting CD38 (daratumumab) and SLAMF7 (elotuzumab) in late 2015 for treating relapsed and refractory multiple myeloma (RRMM) was a critical advance for immunotherapies for multiple myeloma (MM ...
Shih-Feng Cho   +7 more
doaj   +1 more source

Gaps and opportunities in the treatment of relapsed-refractory multiple myeloma: Consensus recommendations of the NCI Multiple Myeloma Steering Committee

open access: yesBlood Cancer Journal, 2022
A wide variety of new therapeutic options for Multiple Myeloma (MM) have recently become available, extending progression-free and overall survival for patients in meaningful ways.
Shaji Kumar   +15 more
doaj   +1 more source

The non-coding RNA landscape of plasma cell dyscrasias [PDF]

open access: yes, 2020
Despite substantial advancements have been done in the understanding of the pathogenesis of plasma cell (PC) disorders, these malignancies remain hard-to-treat.
Azab, Kareem A   +3 more
core   +1 more source

Utility of Bruton’s Tyrosine Kinase Inhibitors in Light Chain Amyloidosis Caused by Lymphoplasmacytic Lymphoma (Waldenström’s Macroglobulinemia)

open access: yesAdvances in Hematology, 2022
Of the variety of immunoglobulin related amyloidosis (AL), immunoglobulin M (IgM) related AL represents only 6 to 10% of affected patients, and the majority of these cases are associated with underlying non-Hodgkin’s Lymphoma including Waldenström’s ...
Maroun Bou Zerdan   +4 more
doaj   +1 more source

Prolyl-tRNA synthetase as a novel therapeutic target in multiple myeloma

open access: yesBlood Cancer Journal, 2023
Multiple myeloma (MM) is a plasma cell malignancy characterised by aberrant production of immunoglobulins requiring survival mechanisms to adapt to proteotoxic stress.
Keiji Kurata   +28 more
doaj   +1 more source

JNK signalling in cancer: In need of new, smarter therapeutic targets [PDF]

open access: yes, 2013
Copyright © 2013 The British Pharmacological Society. This is the accepted version of the following article: Bubici, C. and Papa, S. (2014), JNK signalling in cancer: in need of new, smarter therapeutic targets.
Adams   +137 more
core   +2 more sources

Home - About - Disclaimer - Privacy